Molly -Preconfigured Autoinjector
The establishment of the Molly platform signifies SHL’s commitment to further addressing the varying needs of our customers and their patients. Introduced in 2010, Molly is SHL’s first preconfigured autoinjector designed to help pharmaceutical companies reduce initial investments and expedite development timelines.
Molly features just two simple steps: uncap and inject. As a platform device technology, Molly is supported by SHL’s in-house tooling, assembly, testing, and final assembly infrastructure that is designed to support a fully streamlined product development. Just a year after its launch, Molly went on to win the 2011 Good Design Award, signifying its embodiment of a society-leading good design.
The commonality of Molly’s platform infrastructures has allowed SHL to undertake various overlapping device projects. In 2016 alone, this preconfigured offering has enabled the commercial launch of at least 3 combination products indicated for inflammatory and autoimmune diseases, as well as migraine. With the Molly technology’s vertically integrated development model, SHL also fulfilled the final assembly, labeling, and packaging requirements of the migraine device. These Quick to Market™ services led the migraine device project to advance from device development to clinical delivery in less than nine months.